312 related articles for article (PubMed ID: 15523047)
1. Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity.
Kenny JR; Maggs JL; Tettey JN; Harrell AW; Parker SG; Clarke SE; Park BK
Drug Metab Dispos; 2005 Feb; 33(2):271-81. PubMed ID: 15523047
[TBL] [Abstract][Full Text] [Related]
2. Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.
Kochansky CJ; Xia YQ; Wang S; Cato B; Creighton M; Vincent SH; Franklin RB; Reed JR
Drug Metab Dispos; 2005 Dec; 33(12):1894-904. PubMed ID: 16183782
[TBL] [Abstract][Full Text] [Related]
3. Which hydroxy? Evidence for species differences in the regioselectivity of glucuronidation in rat, dog, and human in vitro systems and dog in vivo.
Martin IJ; Lewis RJ; Bernstein MA; Beattie IG; Martin CA; Riley RJ; Springthorpe B
Drug Metab Dispos; 2006 Sep; 34(9):1502-7. PubMed ID: 16763016
[TBL] [Abstract][Full Text] [Related]
4. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
Kaji H; Kume T
Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
[TBL] [Abstract][Full Text] [Related]
5. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences.
Wen Z; Martin DE; Bullock P; Lee KH; Smith PC
Drug Metab Dispos; 2007 Mar; 35(3):440-8. PubMed ID: 17151190
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma.
Wen Z; Stern ST; Martin DE; Lee KH; Smith PC
Drug Metab Dispos; 2006 Sep; 34(9):1436-42. PubMed ID: 16751262
[TBL] [Abstract][Full Text] [Related]
7. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
Daines RA; Chambers PA; Foley JJ; Griswold DE; Kingsbury WD; Martin LD; Schmidt DB; Sham KK; Sarau HM
J Med Chem; 1996 Sep; 39(19):3837-41. PubMed ID: 8809171
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
[TBL] [Abstract][Full Text] [Related]
9. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide.
Kumar S; Samuel K; Subramanian R; Braun MP; Stearns RA; Chiu SH; Evans DC; Baillie TA
J Pharmacol Exp Ther; 2002 Dec; 303(3):969-78. PubMed ID: 12438516
[TBL] [Abstract][Full Text] [Related]
10. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
11. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.
Prueksaritanont T; Subramanian R; Fang X; Ma B; Qiu Y; Lin JH; Pearson PG; Baillie TA
Drug Metab Dispos; 2002 May; 30(5):505-12. PubMed ID: 11950779
[TBL] [Abstract][Full Text] [Related]
12. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
[TBL] [Abstract][Full Text] [Related]
13. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases.
Tong Z; Li H; Goljer I; McConnell O; Chandrasekaran A
Drug Metab Dispos; 2007 Dec; 35(12):2203-10. PubMed ID: 17875670
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
Kretz-Rommel A; Boelsterli UA
Drug Metab Dispos; 1994; 22(6):956-61. PubMed ID: 7895615
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human.
Brodfuehrer JI; Chapman DE; Wilke TJ; Powis G
Drug Metab Dispos; 1990; 18(1):20-7. PubMed ID: 1970773
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure characterization, and enzyme screening of clenbuterol glucuronides.
Alonen A; Gartman M; Aitio O; Finel M; Yli-Kauhaluoma J; Kostiainen R
Eur J Pharm Sci; 2009 Jul; 37(5):581-7. PubMed ID: 19447177
[TBL] [Abstract][Full Text] [Related]
18. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG
Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787
[TBL] [Abstract][Full Text] [Related]
19. N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.
Yan Z; Caldwell GW; Gauthier D; Leo GC; Mei J; Ho CY; Jones WJ; Masucci JA; Tuman RW; Galemmo RA; Johnson DL
Drug Metab Dispos; 2006 May; 34(5):748-55. PubMed ID: 16455802
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.
Li C; Chauret N; Trimble LA; Nicoll-Griffith DA; Silva JM; MacDonald D; Perrier H; Yergey JA; Parton T; Alexander RP; Warrellow GJ
Drug Metab Dispos; 2001 Mar; 29(3):232-41. PubMed ID: 11181489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
